GNI Group Ltd.
Fiscal Year Ending December 2026 Third Quarter Financial Summary〔IFRS〕(Consolidated)
For the third quarter of the fiscal year ending December 2026, consolidated revenue was 29,731 million yen, a significant year-over-year increase. Operating income turned positive to 73 million yen. With the acquisition of Ayumi Pharmaceutical Holdings as a wholly owned subsidiary and business expansion of Gyre Pharmaceuticals, the Pharmaceuticals segment achieved higher revenue and profit, while the Medical Devices segment saw declines in both revenue and profit. There is no revision to the full-year outlook.
Key Figures
- Revenue: 29,731 million yen (YoY +53.6%)
- Segment Profit (Pharmaceuticals): 3,256 million yen (increase YoY)
- Total Assets: 204,199 million yen, Total Liabilities: 113,954 million yen, Total Equity: 90,245 million yen
AI要約
Overview of Results
In this quarter, changes in the consolidation scope, including the acquisition of Ayumi Pharmaceutical Holdings as a wholly owned subsidiary, led to a substantial increase in revenue. The Pharmaceuticals business saw revenue growth driven by expanded sales of core products such as Kanonal and osteoporosis treatments, and steady performance of the IPF drug Isurui in the Chinese market. Progress was also reported in development and regulatory review for new drug candidates including F351. The Medical Devices business experienced revenue declines due to the impact of Medicare system revisions in the United States. Overall, the Company maintained operating profitability.
Outlook and Impact for Investors
For the second half, the Company will reflect consolidated results including Ayumi Pharmaceutical Holdings while increasing flexibility in development investments. Acceptance of the NDA for F351 in China and advancement of priority review, along with accelerated global expansion, are expected to be key drivers of revenue growth. While increased R&D expenses will pressure short-term earnings, they are positioned as mid- to long-term growth drivers.
Revenue Trend
Operating Income Trend
Segment Revenue Breakdown
Segment Profit Analysis
GNI Group Ltd.
Company overview · Stock price · Financial data · All IR
